Helen I. Torley

Halozyme Therapeutics

President and Chief Executive Officer

Overview

Helen I. Torley received an average compensation of $6,169,450 at Halozyme Therapeutics from 2014 to 2018.

Annual data

2018

In 2018, Helen I. Torley earned a total compensation of $5,799,669 as President and Chief Executive Officer at Halozyme Therapeutics.

Ranking1,088 out of 8,301
Percentile86.9%

Helen I. Torley's 2018 compensation ranked 1,088th out of 8,301 executive pay records tracked by us this year.

Helen I. Torley earned more than 86.9% of all executives tracked by us in 2018.

IndustryBiological products (no diagnostic substances)
Ranking8 out of 84
Percentile90.5%

In the industry of biological products (no diagnostic substances), Helen I. Torley's 2018 pay ranked 8th, among 84 executive pay records.

Helen I. Torley earned more than 90.5% of executives in this industry.

Non-Equity Incentive Plan$831,665
Option Awards$2,115,631
Salary$725,000
Stock Awards$2,115,640
Other$11,733
Total$5,799,669

Torley received $2,115,640 in stock awards, which accounts for 36.48% of total compensation.

Torley also received $831,665 in non-equity incentive plan, $2,115,631 in option awards, $725,000 in salary and $11,733 in other compensation.

Helen I. Torley's Pay$5,799,669
Median Employee's Pay$199,899
Pay Ratio29 : 1

For fiscal year 2018, the annual total compensation for Helen I. Torley was $5,799,669 and for the median employee at Halozyme Therapeutics was $199,899. The resulting ratio of Helen I. Torley's pay to the pay of median employee was 29 to one.

2017

In 2017, Helen I. Torley earned a total compensation of $5,180,551 as President and Chief Executive Officer at Halozyme Therapeutics.

Ranking1,637 out of 13,165
Percentile87.6%

Helen I. Torley's 2017 compensation ranked 1,637th out of 13,165 executive pay records tracked by us this year.

Helen I. Torley earned more than 87.6% of all executives tracked by us in 2018.

IndustryBiological products (no diagnostic substances)
Ranking15 out of 227
Percentile93.4%

In the industry of biological products (no diagnostic substances), Helen I. Torley's 2017 pay ranked 15th, among 227 executive pay records.

Helen I. Torley earned more than 93.4% of executives in this industry.

Non-Equity Incentive Plan$699,115
Option Awards$1,900,003
Salary$671,000
Stock Awards$1,900,011
Other$10,422
Total$5,180,551

Torley received $1,900,011 in stock awards, which accounts for 36.68% of total compensation.

Torley also received $699,115 in non-equity incentive plan, $1,900,003 in option awards, $671,000 in salary and $10,422 in other compensation.

2016

In 2016, Helen I. Torley earned a total compensation of $4,850,075 as President and Chief Executive Officer at Halozyme Therapeutics.

Ranking1,664 out of 13,853
Percentile88.0%

Helen I. Torley's 2016 compensation ranked 1,664th out of 13,853 executive pay records tracked by us this year.

Helen I. Torley earned more than 88.0% of all executives tracked by us in 2018.

IndustryBiological products (no diagnostic substances)
Ranking20 out of 269
Percentile92.6%

In the industry of biological products (no diagnostic substances), Helen I. Torley's 2016 pay ranked 20th, among 269 executive pay records.

Helen I. Torley earned more than 92.6% of executives in this industry.

Non-Equity Incentive Plan$595,448
Option Awards$1,800,037
Salary$645,000
Stock Awards$1,799,998
Other$9,592
Total$4,850,075

Torley received $1,800,037 in option awards, which accounts for 37.11% of total compensation.

Torley also received $595,448 in non-equity incentive plan, $645,000 in salary, $1,799,998 in stock awards and $9,592 in other compensation.

2015

In 2015, Helen I. Torley earned a total compensation of $4,616,787 as President and Chief Executive Officer at Halozyme Therapeutics.

Ranking1,783 out of 13,574
Percentile86.9%

Helen I. Torley's 2015 compensation ranked 1,783rd out of 13,574 executive pay records tracked by us this year.

Helen I. Torley earned more than 86.9% of all executives tracked by us in 2018.

IndustryBiological products (no diagnostic substances)
Ranking30 out of 248
Percentile87.9%

In the industry of biological products (no diagnostic substances), Helen I. Torley's 2015 pay ranked 30th, among 248 executive pay records.

Helen I. Torley earned more than 87.9% of executives in this industry.

Non-Equity Incentive Plan$616,356
Option Awards$1,633,600
Salary$624,000
Stock Awards$1,733,750
Other$9,081
Total$4,616,787

Torley received $1,733,750 in stock awards, which accounts for 37.55% of total compensation.

Torley also received $616,356 in non-equity incentive plan, $1,633,600 in option awards, $624,000 in salary and $9,081 in other compensation.

2014

In 2014, Helen I. Torley earned a total compensation of $10,400,166 as President and Chief Executive Officer at Halozyme Therapeutics.

Ranking479 out of 12,876
Percentile96.3%

Helen I. Torley's 2014 compensation ranked 479th out of 12,876 executive pay records tracked by us this year.

Helen I. Torley earned more than 96.3% of all executives tracked by us in 2018.

IndustryBiological products (no diagnostic substances)
Ranking3 out of 221
Percentile98.6%

In the industry of biological products (no diagnostic substances), Helen I. Torley's 2014 pay ranked 3rd, among 221 executive pay records.

Helen I. Torley earned more than 98.6% of executives in this industry.

Bonus$1,000,000
Non-Equity Incentive Plan$382,500
Option Awards$6,437,200
Salary$593,391
Stock Awards$1,759,200
Other$227,875
Total$10,400,166

Torley received $6,437,200 in option awards, which accounts for 61.90% of total compensation.

Torley also received $1,000,000 in bonus, $382,500 in non-equity incentive plan, $593,391 in salary, $1,759,200 in stock awards and $227,875 in other compensation.